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Dual specificity phosphatase 1 (DUSP1) and the transcription factor NF-kB are implicated in
prostate cancer since their expression levels are altered along this disease, although there
are no evidences up to date demonstrating a crosstalk between them. In this report, we
show for the first time that DUSP1 over-expression in DU145 cells promotes apoptosis
and decreases NF-kB activity by blocking p65/NF-kB nuclear translocation. Moreover,
although DUSP1 impairs TNF-a-induced p38 MAPK and JNK activation, only the specific in-
hibition of p38 MAPK exerts the same effects than DUSP1 over-expression on both
apoptosis and NF-kB activity. Consistently, DUSP1 promotes apoptosis and decreases NF-
kB activity in cells in which p38 MAPK is induced by TNF-a treatment. These results
demonstrate that p38 MAPK is specifically involved in DUSP1-mediated effects on both
apoptosis and NF-kB activity. Interestingly, we show an inverse correlation between
DUSP1 expression and activation of both p65/NF-kB and p38 MAPK in human prostate tis-
sue specimens. Thus, most of apparently normal glands, benign prostatic hyperplasia and
low-grade prostatic intraepithelial neoplasia samples show high DUSP1 expression and
low levels of both nuclear p65/NF-kB and activated p38 MAPK. By contrast, DUSP1 expres-
sion levels are low or even absent in high-grade prostatic intraepithelial neoplasia and
prostatic adenocarcinoma samples, whereas nuclear p65/NF-kB and activated p38 MAPK
are highly expressed in the same samples. Overall, our results provide evidence for a
role of DUSP1 in the apoptosis of prostate cancer cells, through a mechanism involving
the inhibition of p38 MAPK and NF-kB. Furthermore, our findings suggest that the ratiosphatase 1; MAPK, mitogen-activated protein kinase; NF-kB, nuclear factor kb; TNF-a, tumor
cinoma; PIN, prostatic intraepithelial neoplasia; BPH, benign prostatic hyperplasia; PI, pro-
e methyl ester; FITC, fluorescein isothiocyanate; PARP, poly (ADP-ribose) polymerase.
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Published by Elsevier B.V. All rights reserved.1. Introduction into the nucleus, where they bind to specific DNA sequencesProstate cancer is themost commoncancer inmenand the sec-
ond cause of male cancer death (Jemal et al., 2008). Clinical
studies have shown that prostatic adenocarcinoma (PC) needs
a long period to develop fromprostatic intraepithelial neoplasia
(PIN). Initial treatment of this disease is usually partial prosta-
tectomy or radiation to remove or destroy the cancerous cells.
However, in many cases, this cancer recurs in an androgen-
dependent fashion, and the androgen ablation is then the
main therapy. Unfortunately, many patients fail this therapy
and develop recurrent androgen-independent prostate cancer.
In these cases, the lack of effective therapies is related to
poor understanding of the molecular mechanisms underlying
the progression of this disease (Feldman and Feldman, 2001).
Although the complete mechanisms involved in the devel-
opment and progression of prostate cancer are not fully un-
derstood, some of them include the mitogen-activated
protein kinases (MAPK) family (Dhillon et al., 2007). In partic-
ular, p38 MAPK has been previously shown to be involved in
prostate cancer cells, where it controls diverse cellular func-
tions (Boutros et al., 2008), including apoptosis, although its
exact role in this disease appears to be complex. p38 MAPK
activation is achieved by phosphorylation of its catalytic
domain, and down-regulation of its signalling is mediated by
dephosphorylation of this domain by dual specificity phos-
phatases (DUSP) (Keyse, 2000). The founder member of this
family, DUSP1, is an inducible phosphatase that has been
increasingly related to cancer, although its role remains un-
clear (Keyse, 2008). Thus, DUSP1 is over-expressed only in
the early stages of several human tumors, including prostate,
colon and bladder, whereas other cancers show significant
DUSP1 expression even at late stages of the disease (Loda
et al., 1996). Regarding prostate, higher levels of DUSP1 protein
expression have been found in benign prostatic hyperplasia
(BPH) and in PIN, whereas DUSP1 protein and mRNA expres-
sion decreases in parallel with tumor progression and is
almost completely absent in high-grade PC (Rauhala et al.,
2005), as well as in metastasis to the lymph nodes derived
from PC (Magi-Galluzzi et al., 1997). These data suggest that
DUSP1 regulates prostate cancer progression, although, up
to date, there are no mechanistic studies supporting this
hypothesis.
The nuclear factor kB (NF-kB) signalling cascade is a second
marker altered in prostate cancer. In a resting state, NF-kB
proteins are sequestered in the cytoplasm as homo- or heter-
odimers (usually the heterodimer p50/p65) by associationwith
the IkB inhibitory proteins. Cellular stimulation by different
molecules such as the pro-inflammatory cytokine TNF-a acti-
vates an IkB-kinase (IkK) complex to phosphorylate the IkB
proteins. Subsequent poly-ubiquitination and proteasomal
degradation of IkB leads to the translocation of NF-kB dimersmodulating expression of over 150 target genes
(Oeckinghaus et al., 2011). Basal activation of NF-kB has been
observed in several cancers, and its effects have been linked
to proliferation in the absence of growth signals and evasion
of apoptosis (Naugler and Karin, 2008). Analysis of clinical
prostate cancer samples have shown that p65/NF-kB expres-
sion increaseswith the progression of the disease, being nega-
tive in normal prostate samples, low in BPH and low-grade
PIN, and elevated in high-grade PIN and PC (Nunez et al.,
2008; Royuela et al., 2008). This fact correlates with the
increased NF-kB basal activity observed in several prostate
cancer cell lines, which can be enhanced by treatment with
TNF-a (Chopra et al., 2004; Rodriguez-Berriguete et al., 2012).
Moreover, NF-kB activation plays an important role in prostate
cancer cells, since the blockage of this pathway results in
increased apoptosis (Rodriguez-Berriguete et al., 2012).
As mentioned above, several studies with human prostate
cancer specimens have shown that p65/NF-kB levels increase
as the tumor malignancy augments, whereas DUSP1 levels
decrease, however there are no evidences of a connexion be-
tween both events so far. In other tissues, DUSP1 and its target
p38 MAPK, have been shown to be NF-kB regulators. In this
sense, we and other groups have demonstrated that DUSP1
controls NF-kB activation through a mechanism involving
p38 MAPK in tumoral pituitary (Lasa et al., 2010) and pulmo-
nary cells (King et al., 2009). Moreover, p38 MAPK has been
shown to play a role in NF-kB-dependent gene expression in
different cell types (Oeckinghaus et al., 2011). Here, we analyse
whether DUSP1 also regulates NF-kB activity in prostate can-
cer cells, as well as its role on apoptosis, and the mechanisms
underlining this effect. Our data demonstrate for the first time
that DUSP1 promotes apoptosis in DU145 cells, andwe provide
evidences that this effect is specifically mediated by the inhi-
bition of p38 MAPK. In addition, our results show that DUSP1
over-expression significantly decreases NF-kB activity by
blocking p65/NF-kB nuclear translocation in DU145 cells,
through a p38 MAPK-dependent mechanism. Interestingly,
we also demonstrate for the first time a significant inverse cor-
relation between the levels of expression of DUSP1 and both
nuclear p65/NF-kB and activated p38 MAPK in samples from
patients with BPH, high-grade PIN lesions or PC.
In summary, our results demonstrate that re-expression of
DUSP1 in prostate cancer cells is a good strategy to induce
apoptosis, which occurs through a mechanism involving the
inhibition of the p38 MAPK/NF-kB signalling pathway, and
suggest that this phosphatase is a suitable tool to block tumor
progression.Moreover, our data strongly suggest that the ratio
between DUSP1 and p65/NF-kB expression levels, rather than
the individual expression of bothmolecules, represent a more
reliable candidate marker for diagnostic purposes in prostate
cancer.
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2.1. Cell lines, inhibitors, plasmids, transfection and
luciferase assay
DU145 and PC3 prostate cancer cells were purchased from the
American Tissue Culture Collection, (Rockville, MD, USA), and
were cultured as recommended. The inhibitors SB203580,
SB202190 and SP600125 were from Calbiochem (Merck Chem-
icals, Barcelona, Spain). The pCMV-DUSP1 and the 3xNF-kB-
TK-Luc reporter plasmids were previously described (Lasa
et al., 2010; Yano et al., 1987). Cells were transfected with
the plasmids by using Fugene reagent (Promega, Biotech Iber-
ica) as recommended. The NF-kB reporter assays were per-
formed as described (Chiloeches et al., 2008).
2.2. Cell extracts, western blot analysis, antibodies and
quantitative RT-PCR
Nuclear and total cell extracts preparation and Western blot
analysis were performed as previously described with minor
modifications (Chiloeches et al., 2008). The antibodies used
were anti-p65/NF-kB, anti-DUSP1, anti-p38 MAPK, anti-JNK1,
and anti-PARP (Santa Cruz Biotechnology, Heidelberg, Ger-
many); anti-phospho-p38 MAPK (Cell Signalling Technology,
Izasa S.A., Barcelona, Spain); anti-phospho-JNK (Promega,
Promega Biotech Iberica, Madrid, Spain); anti-histone H3
(Abcam, Cambridge, UK); anti-tubulin (Sigma Aldrich, Madrid,
Spain); peroxidase-conjugated secondary antibodies (GE
Healthcare Europe GMBH, Barcelona, Spain).
Total RNA isolation and real-time quantitative RT-PCR val-
idations were performed as previously described (Chiloeches
et al., 2008). The gene-specific primers were as follows:
DUSP1: forward (50-CCT GAC AGC GCG GAA TCT-30), reverse
(50-GAT TTC CAC CGG GCC AC-30); 18S: forward (50-CCA GTA
AGT GCG GGT CAT AAG C-30), reverse (50-CCT CAC TAA ACC
ATC CAA TCG G-30). DDCt method was used to quantify
changes in gene expression, and to calculate the relative
changes normalized against the 18S gene.
2.3. Quantification of sub-G1 DNA content and
apoptosis assays
Quantification of cellular fractions with sub-G1 DNA content
was carried out by flow cytometry analysis of propidium io-
dide (PI)-stained cells. Adherent and floating cells were
collected after treatment, washed with ice-cold PBS, fixed
with 70% ice-cold ethanol, and washed twice with PBS and
treated with RNase (1 mg/ml). Cellular DNA was stained
with PI (5 ng/ml; Sigma Aldrich) and cells were analysed by
flow cytometric analysis. Percentages of cells in different cell
cycle phases were calculated from DNA histograms. Cells
with sub-G1 DNA content were considered apoptotic.
Apoptosis was quantified by the Annexin V/PI dual staining
assay. After transfection and/or treatment, both adherent and
floating cells were incubated with a mixture of fluorescein
isothiocyanate-conjugated annexin V reagent (Annexin V-
FITC, Immunostep, Salamanca, Spain) and PI (3 mM). Samples
were analysed by flow cytometry on a Beckton DickinsonFACScanto flow cytometer (BD Biosciences) and the percent-
ages of Annexin Vþ/PI marked cells were quantified. For
TMRM (tetramethylrhodamine methyl ester) assay, both
adherent and floating cells were loaded with TMRM reagent
(50 nM, Invitrogen, Barcelona, Spain). The percentages of cells
with low mitochondrial membrane potential were measured
by flow cytometric analysis.
2.4. Experimental subjects and immunohistochemistry
of prostate tissues
For immunohistochemical screening, we analysed the
paraffin-embedded samples from patients diagnosed of BPH
(n ¼ 9) or PC (n ¼ 35), most of which had Gleason scores 7.
Approval for the study was obtained from the local ethical
committee. The apparently normal tissue as well as the low-
and high-grade PIN present in the selected samples was also
analysed. Briefly, five-micrometre sections were xylene-
treated and rehydrated in a graded ethanol series. Antigen
retrieval was performed with 10 mM citrate buffer for 3 min.
Endogenous fluorescence was quenched by incubation with
4% sodium borohydride in Tris buffered saline pH 7.6. Non-
specific immunoreactions were prevented by incubation
with blocking solution (3% normal donkey serum, 0.05% triton
X-100 in Tris buffered saline, pH 7.5), and DUSP1, p65/NF-kB or
phospho-p38 MAPK detection was achieved using specific an-
tibodies diluted in blocking solution. After washing, samples
were incubated for 5 min with a rabbit peroxidase-
conjugated secondary antibody (polimer-based system Mas
Vision, Master Diagnostica, Spain), and revealed using 30-dia-
minobenzidine substrate. Staining of nuclei was performed by
using Caracci’s hematoxylin, and negative controls were per-
formed by incubating samples with non-immune rabbit
serum instead of primary antibodies. Sections were coverslip-
ped using a permanent mounting medium (Entellan, Merck).
The immunostaining was ranged into four categories based
on the staining pattern in the majority of tumor cells in the
whole section (0: negative; 1: weakly positive; 2e3: moderately
positive; and 4: highly positive).
2.5. Statistical analysis
All data were expressed as means  standard deviation. The
student’s t test was performed using the SSC-Stat software
(V2.18, University of Reading, United Kingdom). The statistical
significance of difference between groups was expressed by
asterisks (*0.01 < p < 0.05; **0.001 < p < 0.01; ***p < 0.001).3. Results
3.1. DUSP1 promotes apoptosis in DU145 prostate
cancer cells
DUSP1 is an inducible phosphatase that regulates apoptosis in
different tumors, although the molecular mechanisms for its
implication in this process remain controversial (Boutros
et al., 2008). In order to investigate the role of this phosphatase
on survival in prostate cancer cells, we over-expressed DUSP1
in DU145 cell line, as these cells have very low endogenous
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was analysed bymeasuring its mRNA and protein levels in ex-
tracts from cells transfected with a control plasmid or a
plasmid encoding DUSP1. Our data showed a significant in-
crease on both DUSP1 mRNA and protein expression levels
(Figure 1A), thus validating our method for over-expressing
DUSP1 in DU145 cells.
To address the involvement of DUSP1 on apoptosis, we first
examined the proliferation rate in DUSP1-expressing cells,
and our data showed that this phosphatase significantly
reduced proliferation rate over time (Figure 1B). In order to
distinguish between proliferation and survival, we next per-
formed analysis of cell cycle to determine the percentage of
cells in S and G2/M phases in DUSP1-expressing cells. Our
data revealed that DUSP1 over-expression did not affect theFigure 1 eDUSP1 promotes apoptosis in DU145 cells. (A) Cells were transi
DUSP1 (D), total RNA was isolated and the levels of DUSP1 mRNA wer
normalized with 18S mRNA levels and the results were expressed as the fo
analysed by western blotting with antibodies against DUSP1 and tubulin,
indicated times as in (A), and counted. The asterisks show the statistical si
Cells were transfected for 48 h as in (A), and quantification of percentages i
quantification of the results obtained from three independent experiments p
apoptosis was examined by the Annexin V/PI dual-staining assay, as detec
apoptotic (Q4 population). The graph shows the quantification of the results
Cells were transfected for 48 h as in (A) and apoptosis was determined by t
quantification of the results obtained from four independent experiments p
western blotting was performed to analyse PARP cleavage expression, ensu
FITC, Fluorescein isothiocyanate; PI, Propidium iodide; TMRM, tetramethylrhpercentage of cell population in either S or G2/M phases
(Figure 1C). However, this phosphatase decreased the percent-
age of cells in G0/G1 phase and induced a significant increase
on the sub-G1 hypodiploid cell population, reaching a 20%,
compared to the 8% observed in control cells transfected
with the empty vector (Figure 1C). To confirm these results,
we determined the level of phosphatidyl serine exposed
outside the cell membrane by labelling DUSP1-expressing
cells with Annexin V-FITC. Accordingly, our results revealed
that DUSP1 produced a significant increase in basal levels of
Annexin Vþ/PI marked cells, indicative of apoptosis
(Figure 1D). We also examined by TMRM staining the percent-
age of cells undergoing a decrease in mitochondrial mem-
brane potential (DJm), another characteristic parameter of
the process of apoptosis. Our data showed that DUSP1 over-ently transfected for 48 h with a control vector (C) or a vector encoding
e monitored by quantitative RT-PCR. DUSP1 mRNA levels were
ld change in mRNA expression. Total cellular protein lysates were
to assess equal loading protein. (B) Cells were transfected for the
gnificance of differences between the groups: DUSP1 vs. control. (C)
n cell cycle phases was performed by PI staining. The graph shows the
erformed as in (C ). (D) Cells were transfected for 48 h as in (A), and
ted by flow cytometry. Annexin VD/PI- marked cells were considered
obtained from four independent experiments performed as in (D). (E)
he TMRM assay, as detected by flow cytometry. The graph shows the
erformed as in (E ). (F) Cells were transfected for 48 h as in (A), and
ring equal loading with tubulin. The arrow indicates cleaved PARP.
odamine methyl ester.
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DJm from 20% up to 38% (Figure 1E). Finally, we analysed
the effects of DUSP1 on the caspase-mediated cleavage of
poly (ADP-ribose) polymerase (PARP), and observed a signifi-
cant increase of PARP cleavage in DUSP1-expressing cells
(Figure 1F).
To rule out cell-type specific effects of DUSP1, we also stud-
ied its role on apoptosis in PC3 prostate cancer cells, which
neither express this phosphatase in basal conditions, as
observed in DU145 cells. As expected, DUSP1 expression was
only detected after transfection with the plasmid encoding
this phosphatase (Supplementary Figure S1A). Similarly to
the effect observed in DU145 cells, DUSP1 significantly
decreased the proliferation rate of PC3 cells over time
(Supplementary Figure S1B). Moreover, this phosphatase
also promoted apoptosis in these cells, increasing the popula-
tion with low DJm from 7.5% up to 27% (Supplementary
Figure S1C).
Our results altogether show that DUSP1 promotes
apoptosis in different prostate cancer cell lines, revealing a
potential relevance of this phosphatase on prostate cancer
progression.Figure 2 e The inhibition of p38 MAPK specifically induces apoptosis in DU
vector encoding DUSP1, incubated with TNF-a (10 ng/ml) for the indicat
antibodies against both phosphorylated and total p38 MAPK or JNK. (B) C
for 15 min in the absence or presence of TNF-a (10 ng/ml). Total cell lys
phosphorylated and total MAPKAPK-2 (MK2). (C) Cells were incubated w
indicated times. The asterisks show the statistical significance of difference
incubated for 48 h with either SB203580 (1 mM) or SP600125 (10 mM), an
quantification of the results obtained from three independent experiments p
determined as in Figure 1(F). The arrow indicates cleaved PARP.3.2. The inhibition of p38 MAPK specifically induces
apoptosis in DU145 cells
Previous reports have identified p38 MAPK as the major target
for DUSP1 in different cell types (Lang et al., 2006). For this
reason, we next analysed whether p38 MAPK was a target of
DUSP1 also in prostate cancer cells. To carry out these exper-
iments, we used TNF-a as p38MAPK inducer and, as expected,
we observed that this cytokine induced p38 MAPK phosphor-
ylation in a time-dependent manner, while DUSP1 expression
prevented this phosphorylation (Figure 2A). Since DUSP1
inhibited p38 MAPK in DU145 cells, we then studied whether
the inactivation of this kinase by using its specific inhibitor,
SB203580, exerted the same effects than DUSP1 over-
expression on cellular apoptosis. The inhibitory effect of
SB203580 on p38 MAPK activity was confirmed by monitoring
the levels of phospho-MK2 in TNF-a-treated cells incubated
with the inhibitor (Figure 2B). As we observed after DUSP1
over-expression, a significant decrease in cell number was
achieved upon 48 h of treatment with SB203580 (Figure 2C).
Since previous reports had already shown that incubation of
different prostate cancer cells in the presence of SB203580145 cells. (A) Cells were transfected for 48 h with a control vector or a
ed times and total cell lysates were analysed by western blotting with
ells were incubated for 48 h with SB203580 (1 mM), and then treated
ates were analysed by western blotting with antibodies against both
ith either SB203580 (1 mM) or SP600125 (10 mM) and counted at the
s between the groups: SB vs. control or SP vs. control. (D) Cells were
d apoptosis was assayed by the TMRM assay. The graph shows the
erformed as in (D). (E) Cells were treated as in (D), and apoptosis was
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 2 7e3 832inhibitor does not affect the distribution of cells either in the S
or G2/M phases (Rodriguez-Berriguete et al., 2012; Shin et al.,
2012; Sun et al., 2010), we next determine the involvement of
p38 MAPK on cellular apoptosis, by measuring the number
of cells with low DJm after incubation with the SB203580 in-
hibitor. Our data indicated that the population showing low
DJm significantly increased after incubation with the p38
MAPK inhibitor, compared to control cells (38% vs. 19%;
Figure 2D). To verify that blockage of p38 MAPK induced
apoptosis, we also examined the effect of SB203580 inhibitor
on PARP cleavage. The obtained data confirmed that the abro-
gation of p38 MAPK activity achieved by incubation with the
SB203580 inhibitor increased PARP cleavage (Figure 2E). The
pro-apoptotic role of p38 MAPK inhibition in DU145 cells was
further investigated by using another specific pharmacolog-
ical inhibitor of this kinase in these cells, SB202190 (Chen
et al., 2012; Mehta et al., 2001). As expected, our data showed
that this inhibitor exerted similar effects on cellular apoptosis
than either the SB203580 inhibitor or DUSP1 over-expression
(Supplementary Figure S2).
DUSP1 over-expression could be regulating cellular
apoptosis by affecting pathways different from p38 MAPK,
such as JNK. For this reason, we analysed whether JNK was
also a target of DUSP1 in DU145 cells. First, we observed that
TNF-a induced JNK phosphorylation in a time-dependent
manner and DUSP1 expression prevented it (Figure 2A). We
then studied whether the inactivation of this kinase by using
its specific inhibitor, SP600125, exerted the same effects than
DUSP1 expression on cellular apoptosis. To this purpose, we
examined the proliferation rate, and we observed that the
SP600125 inhibitor caused a significant decrease in cell num-
ber after 48 h of treatment (Figure 2C). However, in contrast
to what happened with p38 MAPK inhibition, the inactivation
of JNK did not significantly affect either the percentage of pop-
ulation showing low DJm (19.7% vs. 18.4%; Figure 2D), or the
PARP cleavage (Figure 2E).
These results altogether demonstrate that the inhibition of
p38 MAPK, but not that of JNK, and the over-expression of
DUSP1 exert the same effects on apoptosis in DU145 cells, sug-
gesting that this phosphatase regulates this process by specif-
ically inhibiting p38 MAPK.
3.3. DUSP1 induces apoptosis in DU145 cells through
the inhibition of p38 MAPK
Since we had demonstrated that TNF-a induced p38 MAPK ac-
tivity in DU145 cells, and DUSP1 over-expression inhibited it,
we next analysed the effect of DUSP1-mediated inhibition of
p38 MAPK on the apoptosis of cells in which this kinase was
activated by treatment with TNF-a. To this purpose, we deter-
mined the sub-G1 hypodiploid cell population in DUSP1-
expressing cells treated with TNF-a. Our data showed that
treatment with this cytokine of cells transfected with the
empty vector did not significantly modify either the sub-G1
population, or the percentage of cells in G0/G1 S and G2/M
phases (Figure 3A). Moreover, similarly to the effect of
DUSP1 in basal cells, this phosphatase did not affect cell pop-
ulation in either S or G2/M phases in TNF-a-treated cells,
whereas it decreased the percentage of cells in G0/G1 phase,
and increased the sub-G1 hypodiploid cell population up toabout 21% in TNF-a-treated cells (Figure 3A). To confirm these
results, we determined the apoptosis level after labelling cells
with Annexin V-FITC under the same conditions. As expected,
the results revealed that DUSP1 produced a significant in-
crease in the levels of Annexin Vþ/PI marked cells treated
with TNF-a, when compared to cells expressing the empty
vector in which p38 MAPK was also activated by incubation
with TNF-a (Figure 3B). Finally, we also examined the percent-
age of cells with low DJm, and our data confirmed that DUSP1
over-expression significantly increased the number of
apoptotic cells after TNF-a treatment (Figure 3C).
In order to analyse whether DUSP1 also induced apoptosis
in TNF-a-treated PC3 cells, we carried out similar experiments
to those performed in DU145 cells. Our results showed that
DUSP1 prevented the phosphorylation of p38 MAPK induced
by TNF-a, and suggested that this kinase is the mediator of
DUSP1 effects also in these cells (Supplementary
Figure S1D). Moreover, similarly to what happened in DU145
cells, DUSP1 over-expression also significantly reduced the
proliferation rate (Supplementary Figure S1E), and promoted
apoptosis (Supplementary Figure S1F) in TNF-a-treated PC3
cells.
Taken together, these data demonstrate that DUSP1 over-
expression induces apoptosis in prostate cancer cells through
the inhibition of p38 MAPK.
3.4. DUSP1 regulates the NF-kB pathway in DU145 cells
through p38 MAPK inhibition
NF-kB is an important survival regulator in prostate cancer
cells (Chopra et al., 2004; Rodriguez-Berriguete et al., 2012),
which is activated by p38 MAPK in several cellular contexts
(Baeza-Raja and Munoz-Canoves, 2004; Calleros et al., 2006;
King et al., 2009; Lasa et al., 2010; Vanden Berghe et al.,
1998). Because we had demonstrated that DUSP1 impaired
p38 MAPK activity, and this inhibition promoted apoptosis in
DU145 cells, we wondered whether the inhibition of p38
MAPK, achieved by either treatment with SB203580 or DUSP1
over-expression, also prevented NF-kB activity in these cells.
To this purpose, we first performed experiments to determine
the effect of the specific p38 MAPK inhibitor, SB230580, on NF-
kB activity. The results demonstrated that TNF-a significantly
increased NF-kB activity by about four fold, and the treatment
with the SB203580 inhibitor prevented both basal and TNF-a-
induced NF-kB activity (Figure 4A). To confirm the regulation
of NF-kB activity by p38 MAPK, we also measured p65/NF-kB
nuclear translocation in cells treated with the SB203580 inhib-
itor. As expected, TNF-a increased p65/NF-kB nuclear levels
and SB203580 partially prevented this effect (Figure 4B). These
results were verified by using another specific p38 MAPK in-
hibitor, SB202190, which was also able to impair the entry of
p65/NF-kB to the nucleus (Supplementary Figure S3).
Next, we studied whether the inhibition of p38 MAPK by
DUSP1 over-expression also affected NF-kB activity. First, we
demonstrated that over-expression of this phosphatase
significantly reduced NF-kB activity by about 50% in basal con-
ditions. Moreover, DUSP1 abolished the induction of NF-kB
achieved upon p38 MAPK activation by TNF-a treatment
(Figure 4C). Furthermore, we examined the effect of DUSP1
on TNF-a-induced p65/NF-kB nuclear translocation, and found
Figure 3 e DUSP1 induces apoptosis in DU145 cells through the inhibition of p38 MAPK. (A) Cells were transfected with a control vector or a
vector encoding DUSP1, incubated with TNF-a (10 ng/ml) for 48 h, and quantification of percentages in cell cycle phases was assayed as in
Figure 1(C). The graph shows the quantification of the results obtained from three independent experiments. (B) Cells were transfected and treated
as in (A), and apoptosis was examined as in Figure 1(D). The graph shows the quantification of the results obtained from four independent
experiments. (C) Cells were transfected and treated as in (A), and apoptosis was examined as in Figure 1(E). The graph shows the quantification of
the results obtained from four independent experiments.
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 2 7e3 8 33that DUSP1 over-expression strongly reduced p65/NF-kB nu-
clear levels (Figure 4D). Finally, to further confirm the role of
DUSP1 in NF-kB activation in prostatic tumor cells, we overex-
pressed DUSP1 in PC3 cells. Similarly to the effect observed in
DU145 cells, DUSP1 over-expression in PC3 cells significantly
reduced NF-kB-dependent transcription, both in basal and
TNF-a-treated cells (Figure 4E).
The observed partial effect of SB203580 inhibitor prevent-
ing TNF-a-induced NF-kB activation and p65/NF-kB nucleartranslocation could be indicating that DUSP1 over-
expression would be regulating alternative pathways such
as JNK, which in turn could affect NF-kB activation. We
next analyzed this possibility, and, opposite to the data
observed after inhibition of p38 MAPK, our results showed
that the blockage of JNK activation using the specific inhibitor
SP600125 did not impair either TNF-a-mediated NF-kB tran-
scriptional activation (Figure 4A) or the translocation of





































































































Figure 4 e DUSP1 regulates the NF-kB pathway in DU145 cells through p38MAPK inhibition. (A) DU145 cells were transfected with the NF-kB
luciferase reporter plasmid and the pRL-TK-Renilla plasmid. Cells were incubated for 48 h with either SB203580 (1 mM) or SP600125 (10 mM),
treated in the absence or presence of TNF-a (10 ng/ml) during the last 6 h, and cell extracts were prepared and assayed for luciferase and renilla
activities. The luciferase levels were normalized to those of renilla, and were expressed as the induction over the controls. (B) DU145 cells were
incubated for 48hwith either SB203580 (1mM)orSP600125 (10mM)and then treatedwithTNF-a (10ng/ml) for the indicated times.Nuclear extracts
were analysed by western blotting using antibodies against p65. The levels of tubulin and histone H3 were determined as controls to validate the
integrity of the cytosolic andnuclear fractions, respectively. (C)DU145cellswere co-transfected for 48hwith the plasmids described in (A) and a vector
encoding DUSP1, then incubated with TNF-a (10 ng/ml) for the last 6 h, processed and analysed as in (A). (D) DU145 cells were transfected for 48 h
with a vector encodingDUSP1 and then incubatedwithTNF-a (10 ng/ml) for the indicated times.The cytosolic extracts (CE) and the nuclear extracts
(NE) were analysed by western blotting using antibodies against p65. The levels of tubulin and histoneH3 were determined as controls to validate the
integrity of the cytosolic and nuclear fractions, respectively. (E) PC3 cells were co-transfected for 48 h with the plasmids described in (A) and a vector
encoding DUSP1, then incubated with TNF-a (10 ng/ml) for the last 6 h, processed and analysed as in (A).
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 2 7e3 834(Figure 4B). These data indicate that the inhibitory effect on
NF-kB activity achieved by DUSP1 over-expression is not
mediated by the abrogation of JNK activity induced by this
phosphatase.
These results altogether demonstrate that DUSP1 nega-
tively regulates NF-kB activity in DU145 cells by decreasing
p65/NF-kB nuclear translocation, through a mechanism
involving p38 MAPK inhibition.
3.5. DUSP1 expression inversely correlates with both
nuclear p65/NF-kB and activated p38 MAPK in human
prostate tissue specimens
Our results strongly suggested that p65/NF-kB activity is
dependent on DUSP1 expression. To investigate the relevance
of such regulation in samples frompatientswith prostate can-
cer, we analysed the distribution of DUSP1 and p65/NF-kB in a
series of human prostate tissue specimens. The results of
DUSP1 or p65/NF-kB immunohistochemical stainings
appeared to be very similar between the cohorts. Themajority
of BPH and low-grade PIN samples showed a weak expression
of p65/NF-kB (Figure 5A-a, d ), and a high DUSP1 expression
(Figure 5A-b, e). Conversely, a moderate-high p65/NF-kBexpression was detected in high-grade PIN (Figure 5A-g),
whereas DUSP1 expression was lower in the same samples
(Figure 5A-h). In addition, most of the invasive PC samples
showed high p65/NF-kB expression (Figure 5A-j ), reaching
the maximum level in androgen-resistant PC (Figure 5A-m).
By contrast, DUSP1 expression was very weak or even unde-
tectable in these PC specimens (Figure 5A-k,n). Activation of
p65/NF-kB in human samples was demonstrated by analysing
its nuclear localization, which was evident in 77% of the spec-
imens studied (Supplementary Figure S4). Considering all the
samples tested (n¼ 35), the percentage of them showing an in-
verse correlation between p65/NF-kB and DUSP1 expression
levels was about 80% (Figure 5B). This inverse correlation
was even more significant when considering only samples
from patients developing the most aggressive disease
(androgen-resistant PC, positive node and metastatic sam-
ples). In these cases (n ¼ 13), 92% of samples showed high
levels of p65/NF-kB expression and very low or even absent
DUSP1 expression (Figure 5C).
Because our results in prostate cancer cells revealed that
DUSP1 negatively regulates NF-kB activity through a mecha-
nism involving p38 MAPK inhibition, we also analysed the
level of phospho-p38 MAPK in the same samples in which
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 2 7e3 8 35the expression of both DUSP1 and p65/NF-kB was studied. Our
data indicated that the level of activated p38 MAPK was lower
in BPH and low-grade PIN samples (Figure 5A-c, f), while most
of the high-grade PIN and invasive PC samples showed high
levels of activated p38 MAPK (Figure 5A-i, l, o).Figure 5 eDUSP1 expression inversely correlates with both nuclear p65/NF
Immunohistochemical analysis of p65, DUSP1 and phospho-p38 MAPK exp
of all samples tested (n [ 35) expressing different levels of both p65 and D
expressing different levels of both p65 and DUSP1. The immunostaining i
categories based on the staining pattern in the majority of tumor cells in the
and DDDD, highly positive). BPH: benign prostatic hyperplasia; LG-PIN
prostatic intraepithelial neoplasia; PC: prostatic adenocarcinoma; HR-PC: hoCollectively, these results indicate an inverse correlation
between DUSP1 expression levels and both p65/NF-kB and
p38 MAPK activity in human prostate tissue specimens. Inter-
estingly, these data support our experiments in prostate can-
cer cells demonstrating that DUSP1 is an NF-kB inhibitor, and-kB and activated p38 MAPK in human prostate tissue specimens. (A)
ression levels from human prostate cancer specimens. (B) Percentages
USP1. (C) Percentages of samples with the worst prognosis (n [ 13)
ntensities in (B) and (C ) are indicated by crosses ranged into four
whole section (D, weakly positive or absent;DD, moderately positive;
: low-grade prostatic intraepithelial neoplasia; HG-PIN: high-grade
rmone-resistant prostatic adenocarcinoma.
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 2 7e3 836suggest that the ratio between the expression levels of both
proteins is an important marker for diagnostic purposes in
prostate cancer.4. Discussion
The phosphatase DUSP1 is becoming an important molecule
in multiple types of human cancer due to its differential
expression and to its regulation of the MAPK signalling path-
ways, which have been shown to be involved in this disease
(Boutros et al., 2008). In prostate cancer, the expression of
DUSP1 is high in BPH or PIN lesions, and low or even absent
in high-grade PC (Rauhala et al., 2005), although the relevance
of this differential expression has been unknown so far. Here,
we demonstrate by different approaches that the over-
expression of DUSP1 induces apoptosis in DU145 and PC3 can-
cer cells, which are in vitromodels that resemble the late stage
of PC. In agreement with our data, it has been shown that the
up-regulation of DUSP1 in several breast cancer cells is
involved in the apoptosis induced by either the proteasome
inhibitor Z-LLF-CHO (Orlowski et al., 2002) or nitric oxide
(Pervin et al., 2003). In addition, DUSP1 over-expression in-
duces apoptosis in MCF7 breast cancer cells (Wang et al.,
2007) and in colon cancer cells (Liu et al., 2008). Moreover,
we have previously demonstrated that the induction of
DUSP1 in pituitary tumor cells is crucial in thyroid hormone-
mediated apoptosis (Chiloeches et al., 2008). However, the
role of DUSP1 in the apoptosis of cancer cells is controversial,
since this phosphatase also seems to be important to prevent
the cell death induced by chemotherapy agents in diverse tu-
mor cells (Chattopadhyay et al., 2006; Wang et al., 2006; Wu
et al., 2005).
The pro-apoptotic role of DUSP1 demonstrated here is
consistent with a recent report showing that photodynamic
therapy of DU145 cells induces apoptosis and up-regulates
DUSP1 gene transcription (Kammerer et al., 2011), but is in
contradiction with a report showing that this phosphatase
blocks Fas Ligand-induced apoptosis in these cells (Srikanth
et al., 1999). Although these authors do not deeply analyse
the mechanism underlying the anti-apoptotic effect of
DUSP1 in DU145 cells, the apparent controversy with our
data could be explained by the fact that p38 MAPK seems
not to be involved in the regulation of Fas Ligand-induced
apoptosis by this phosphatase (Srikanth et al., 1999). p38
MAPK has been identified as the major target for DUSP1 in
different cellular contexts activated by the cytokine TNF-a
(Lang et al., 2006), although the role of this kinase on
apoptosis in tumor cells is still controversial. In this report,
we provide three lines of evidence demonstrating that
DUSP1-induced apoptosis in DU145 cells is mediated by the
inhibition of p38 MAPK. (i) DUSP1 over-expression abolishes
TNF-a-induced activation of p38 MAPK. (ii) The specific inhib-
itors of p38 MAPK, SB203580 and SB202190, exert the same ef-
fects than the phosphatase on apoptosis. (iii) DUSP1 over-
expression also promotes apoptosis in cells in which p38
MAPK is activated by treatment with TNF-a. Consistently
with our data, it has been shown that this MAPK mediates
cell survival in several tumor cells (Wagner and Nebreda,
2009). In reference to prostate cancer, our results are similarto those reported by other groups showing that the inhibition
of p38 MAPK induces apoptosis in the androgen-dependent
LNCaP prostate cancer cells (Ricote et al., 2006; Rodriguez-
Berriguete et al., 2012). Moreover, knocking down p38 MAPK
by specific siRNA significantly sensitizes LNCaP cells to
docetaxel-induced apoptosis through a p53-dependent
mechanism (Gan et al., 2011). Our data also demonstrate
that JNK is not involved in the promotion of apoptosis
induced by DUSP1. Although this phosphatase reduces
TNF-a-induced activation of both p38MAPK and JNK, the spe-
cific inhibitor of JNK, SP600125, does not promote apoptosis
in these cells. These results are in agreement with other re-
ports showing no effect of this kinase on apoptosis in
DU145 cells (Curtin and Cotter, 2004; Ricote et al., 2006; Xiao
et al., 2004). Despite the lack of effect of JNK on apoptosis in
DU145 cells, we have observed that the JNK inhibitor highly
decreases cell number. Our data are consistent with a previ-
ous report showing that this inhibitor affects proliferation by
arresting cells in the G2/M phase of the cell cycle in several
cell lines, including DU145 cells (Ennis et al., 2005).
On the other hand, the transcription factor NF-kB is crucial
in prostate tumors, since the increase of its activity has been
shown to be responsible for the induction of tumor growth,
evasion of apoptosis and promotion of metastasis (Naugler
and Karin, 2008). Moreover, histopathological analysis of hu-
man prostate cancer specimens have demonstrated high
levels of p65/NF-kB expression in samples from patients
with high-grade PC, in comparison to normal prostate or
BPH lesions (Nunez et al., 2008). Consistently, different studies
have identified a constitutive activation of NF-kB in several
human PC cells (Gasparian et al., 2002). Here, we demonstrate
a close relationship between NF-kB and DUSP1, since over-
expression of this phosphatase inhibits NF-kB activity in
DU145 cells by affecting the p65/NF-kB translocation to the
nucleus. These results are similar to previous data showing
that DUSP1 impairs NF-kB activity in pituitary tumor cells
(Chiloeches et al., 2008; Lasa et al., 2010) and pulmonary cells
(King et al., 2009). The regulation of NF-kB pathway by DUSP1
is not surprising considering that this protein is associated to
the IkK proteins in different cell types (Kosaka et al., 1999;
Mercurio et al., 1997; Woronicz et al., 1997). However, we
have not detected any change in the activity of IkK a/b after
DUSP1 over-expression, and we have not seen any interaction
between DUSP1 and IkK a/b in DU145 cells (data not shown).
These findings strongly suggest that DUSP1 could inhibit NF-
kB activity in prostate cancer cells by an IkK-independent
mechanism, perhaps affecting the atypical NF-kB pathway,
in which p38 MAPK activates p65/NF-kB through the phos-
phorylation and activation of the casein kinase 2 (Kato et al.,
2003). This hypothesis is quite plausible since our data
demonstrate that DUSP1 inhibits p38 MAPK in DU145 and
PC3 cells, and the blockage of this kinase down-regulates
NF-kB activity. In agreement with our results, previous studies
have shown that p38 MAPK activation allows p65/NF-kB nu-
clear translocation in several cell types (Baeza-Raja and
Munoz-Canoves, 2004; Calleros et al., 2006; King et al., 2009;
Lasa et al., 2010; Vanden Berghe et al., 1998). These data alto-
gether open the possibility to study the interaction between
DUSP1 and p38 MAPK/CK2/NF-kB signalling pathway in pros-
tate cancer cells.
M O L E C U L A R O N C O L O G Y 8 ( 2 0 1 4 ) 2 7e3 8 37The importance of the observed crosstalk between DUSP1
and NF-kB in prostate cancer cells is supported by the analysis
of the expression levels of both DUSP1 and p65/NF-kB in the
same clinical samples from patients with prostate cancer at
different stages. Interestingly, we have found a strong inverse
correlation between the expression of both DUSP1 and p65/
NF-kB proteins almost in all the groups of human specimens
analysed (BPH, PIN and PC). We show that DUSP1 is highly
expressed in BPH lesions, whereas p65/NF-kB expression is
low. Moreover, this correlation is progressively inversed with
tumor malignancy, reaching a higher p65/NF-kB expression
and lower DUSP expression in high-grade PC. As expected,
our data also demonstrate an inverse correlation between
the expression of both DUSP1 and activated p38 MAPK. These
results altogether reinforce the relevance of our findings
demonstrating the role of DUSP1 as NF-kB inhibitor in prostate
cancer. They also suggest that NF-kB is down-regulated in
benign lesions as a result of the increased expression of
DUSP1 and the decreased p38 MAPK activation, whereas NF-
kB levels augment in high-grade PC samples, where the
expression of DUSP1 is low or even absent, and the activation
of p38 MAPK is increased. Interestingly, our data show a high
correlation between the absence of DUSP1 and the level of
androgen-resistance in 92% of tested tumors, suggesting the
existence of a crosstalk between DUSP1 and androgen recep-
tor signalling pathways. Consistent with the low levels of
DUSP1 in response to androgen ablation, this phosphatase
has been found to be up-regulated upon androgen treatment
in LNCaP cells (Vaarala et al., 2012), although the implication
of such regulation in prostate cancer remains to be
established.
In conclusion, the results shown here demonstrate that re-
expression of DUSP1 is a good strategy to inhibit NF-kB signal-
ling in prostate cancer, and to decrease the survival of pros-
tate cancer cells, contributing to reduce tumor progression.
Moreover, our data strongly suggest that the ratio between
DUSP1 and p65/NF-kB expression levels, rather than the indi-
vidual expression of both molecules, represents a more reli-
able marker for diagnostic purposes in prostate cancer.5. Conclusions
- The phosphatase DUSP1 promotes apoptosis in prostate
cancer cells through the inhibition of p38 MAPK.
- The phosphatase DUSP1 negatively regulates NF-kB ac-
tivity in prostate cancer cells by decreasing p65/NF-kB
nuclear translocation, through a mechanism involving
p38 MAPK inhibition.
- DUSP1 expression inversely correlates with nuclear p65/
NF-kB and p38 MAPK activity in human prostate tissue
specimens. This suggests that the ratio between the
expression levels of DUSP1 and p65/NF-kB is an important
marker for diagnostic purposes in prostate cancer.Conflict of interest
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